Eli Lilly’s quarter was messy. What to do with the stock is more clear-cut

Earnings

Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.
Cristina Arias | Cover | Getty Images

Eli Lilly shares fell Wednesday after the diabetes-and-obesity drug giant posted disappointing third-quarter results and lowered its full-year sales guidance. The report was messy, but it doesn’t dim Eli Lilly’s bright multiyear outlook, rendering the dip in the stock as a chance to buy.

Articles You May Like

How the world’s 431 women billionaires make, spend and give away their fortunes
Data centers powering artificial intelligence could use more electricity than entire cities
Wall Street analysts tout our 2 cybersecurity stocks ahead of quarterly earnings
Walmart may have to raise some prices if Trump tariffs take effect, CFO says
How Much Money Do I Need To Retire At 55?

Leave a Reply

Your email address will not be published. Required fields are marked *